AI English summary of an SEC filing — figures as filed
Baxter International BAXThe company said it completed on January 31, 2025 the sale of all issued and outstanding equity interests of the Divested Entities, including Vantive Health LLC, to the Buyer, consisting of Spruce Bidco I, Inc. and others, under the previously announced transaction.
Key points
AI summaryThe company said it completed on January 31, 2025 the sale of all issued and outstanding equity interests of the Divested Entities, including Vantive Health LLC, to the Buyer, consisting of Spruce Bidco I, Inc. and others, under the previously announced transaction.
The company said the total purchase price agreed with the Buyer at signing was $3.80 billion in cash (before adjustments for closing cash, working capital and debt), and that it received approximately $3.71 billion of net pre-tax cash at closing after adjustments. Post-closing adjustments are possible.
The company said the First Amendment provides that the closing of the purchase and sale of the Interests (excluding transactions completed at a Local Closing) takes effect at 11:59 p.m. Eastern Time on January 31, 2025.
The company said that, as of the Closing Date, unvested awards held by Vantive Transferred Business Employees vested pro rata based on the calendar days elapsed in the vesting period, and that the Buyer is obligated to grant cash-based replacement awards for the forfeited portion. Chris Toth left his position as Executive Vice President and Group President, Kidney Care, and his role as a company officer on the same day.
Summary
AI-writtenAnalysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.
Baxter completes sale of all equity in Vantive Health and other divested entities
The company said it completed on January 31, 2025 the sale of all issued and outstanding equity interests of the Divested Entities, including Vantive Health LLC, to the Buyer, consisting of Spruce Bidco I, Inc. and others, under the previously announced transaction.
Source · Based on the filing body and exhibits
Total purchase price of $3.80 billion, net pre-tax cash of about $3.71 billion
The company said the total purchase price agreed with the Buyer at signing was $3.80 billion in cash (before adjustments for closing cash, working capital and debt), and that it received approximately $3.71 billion of net pre-tax cash at closing after adjustments. Post-closing adjustments are possible.
Source · Based on the filing body and exhibits
Effective time of sale under First Amendment
The company said the First Amendment provides that the closing of the purchase and sale of the Interests (excluding transactions completed at a Local Closing) takes effect at 11:59 p.m. Eastern Time on January 31, 2025.
Source · Based on the filing body and exhibits
LTIP Award Treatment and Chris Toth's departure as officer
The company said that, as of the Closing Date, unvested awards held by Vantive Transferred Business Employees vested pro rata based on the calendar days elapsed in the vesting period, and that the Buyer is obligated to grant cash-based replacement awards for the forfeited portion. Chris Toth left his position as Executive Vice President and Group President, Kidney Care, and his role as a company officer on the same day.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…